NASA’s Artemis program may be in the lead, but China could still win the new moon race

Artemis II is nearing splashdown after a successful circumlunar flyby, while on Feb 11 China performed a successful single-stage Long March 10 and Mengzhou in-flight abort test plus a controlled propulsive booster splashdown. China has also tested the Lanyue lander and aims for a crewed lunar landing before 2030, planning dual Long March 10 launches to rendezvous in lunar orbit; Mengzhou variants could carry 6–7 astronauts to LEO or three to low lunar orbit. These developments heighten strategic competition in aerospace/defense and could influence supplier and national program priorities, though near-term market pricing impact is likely limited.

Analysis

China’s centralized, end-to-end approach to crewed lunar capability compresses programmatic optionality: a single political decision can accelerate hardware integration and scale manufacturing capacity in a way the fragmented U.S. ecosystem cannot. That creates a two-track market dynamic over the next 12–36 months — increased government contracting for traditional primes and simultaneous price-pressure on commercial small-launch and niche suppliers as China verticalizes its stack.

Second-order supply-chain winners are not the headline rocket builders but subsystem and payload integrators that scale with recurrent lunar test flights: precision avionics, propulsive landing systems, and high-reliability space-grade composites. Expect meaningful revenue cadence inflection points tied to China’s upcoming full Long March 10 orbital tests (months) and to NASA commercial lander award decisions (quarters), each capable of driving 20–40% order-book re-rating for exposed suppliers.

Tail risks center on single-event failures and geopolitics. A catastrophic test failure, export-control tightening, or a U.S. congressional funding pivot could reverse momentum within weeks-to-months; conversely, a successful Starship certification or a Chinese crewed lunar sortie before 2030 would accelerate consolidation and premium valuation for firms that secure long-term logistics/lander work. The most likely asymmetry: investors are underpricing program risk concentration in China and underestimating the upside for established primes that capture the inevitable surge in government-funded cislunar logistics over the next 2–5 years.

Key Decisions for Investors

• Overweight Lockheed Martin (LMT), Northrop Grumman (NOC), Raytheon Technologies (RTX) — increase exposure over 6–24 months via 12–18 month LEAPS calls or a 3–5% portfolio tilt. Rationale: durable government backlog and prime-integrator optionality; downside risk: program cancellations or budget cuts (~10–20% drawdown).
• Buy Maxar Technologies (MAXR) — 6–24 month horizon via outright shares or 9–12 month call options sized as a tactical 1–2% position. Rationale: lunar mapping, payload integration and data services optionality unlockable on successful cis-lunar missions; risk: launch delays and capex cycles could compress near-term cash flow.
• Pair trade: long LMT (notional) / short Rocket Lab (RKLB) (equal notional) — 6–12 month horizon. Rationale: primes should capture increased NASA/DoD cislunar spend while smaller launch providers face pricing competition and margin pressure; set protective stops at 12–15% on the short leg if RKLB wins larger commercial share.
• Maintain a 1–2% portfolio hedge in aerospace insurance/contingent-liability protection (select catastrophe bond or sector put spread) to protect against single-event catastrophic test failures or debris incidents that would temporarily freeze programs and re-rate sector multiples.